首页> 外文会议>Biophotonics and immune responses IV >Studying tumor metastasis by in vivo imaging and flow cytometer
【24h】

Studying tumor metastasis by in vivo imaging and flow cytometer

机译:通过体内成像和流式细胞仪研究肿瘤转移

获取原文
获取原文并翻译 | 示例

摘要

Liver cancer is one of the most common malignancies in the world, with approximately 1,000,000 cases reported every year. This ranges from 15,000 cases in the United States to more than a 250,000 in China. About 80% of people with primary liver cancer are male. Although two-thirds of people have advanced liver disease when they seek medical help, one third of the patients have cancer that has not progressed beyond the liver. Primary liver cancer (hepatocellular carcinoma, or HCC) is associated with liver cirrhosis 60-80% of the time. HCC may metastasize to the lung, bones, kidney, and many other organs. Surgical resection, liver transplantation, chemotherapy and radiation therapy are thernfoundation of current HCC therapies. However the outcomes are poor : the survival rate is almost zero for metastatic HCC patients. Molecular mechanisms of HCC metastasis need to be understood better and new therapies must be developed to selectively target to unique characteristics of HCC cell growth and metastasis. We have developed the "in vivo microscopy" to study the mechanisms that govern liver tumor cell spread through the microenvironment in vivo in real-time confocal near-infrared fluorescence imaging. A recently developed "in vivo flow cytometer" and optical imaging are used to assess liver tumor cell spreading and the circulation kinetics of liver tumor cells. A real- time quantitative monitoring of circulating liver tumor cells by the in vivo flow cytometer will be useful to assess the effectiveness of the potential therapeutic interventions.
机译:肝癌是世界上最常见的恶性肿瘤之一,每年报告约一百万例。从美国的15,000例到中国的25万以上。大约80%的原发性肝癌患者是男性。尽管三分之二的人在寻求医疗帮助时患有晚期肝病,但仍有三分之一的患者患有肝癌。原发性肝癌(肝细胞癌或HCC)有60-80%的时间与肝硬化相关。 HCC可能转移到肺,骨骼,肾脏和许多其他器官。手术切除,肝移植,化学疗法和放射疗法是当前HCC治疗的基础。但是结果却很差:转移性HCC患者的生存率几乎为零。需要更好地了解肝癌转移的分子机制,必须开发新的疗法以选择性靶向肝癌细胞生长和转移的独特特征。我们已经开发了“体内显微镜”,以研究在实时共聚焦近红外荧光成像中通过微环境在体内控制肝肿瘤细胞扩散的机制。最近开发的“体内流式细胞仪”和光学成像用于评估肝肿瘤细胞的扩散和肝肿瘤细胞的循环动力学。通过体内流式细胞仪实时定量监测循环肝肿瘤细胞将有助于评估潜在治疗干预措施的有效性。

著录项

  • 来源
    《Biophotonics and immune responses IV》|2009年|71780E.1-71780E.7|共7页
  • 会议地点 San Jose CA(US)
  • 作者单位

    Institutes of Biomedical Sciences, Fudan University, 138 Yi Xue Yuan Road, Shanghai, China 200032;

    Institutes of Biomedical Sciences, Fudan University, 138 Yi Xue Yuan Road, Shanghai, China 200032;

    Institutes of Biomedical Sciences, Fudan University, 138 Yi Xue Yuan Road, Shanghai, China 200032;

    Institutes of Biomedical Sciences, Fudan University, 138 Yi Xue Yuan Road, Shanghai, China 200032;

    Institutes of Biomedical Sciences, Fudan University, 138 Yi Xue Yuan Road, Shanghai, China 200032;

    Institutes of Biomedical Sciences, Fudan University, 138 Yi Xue Yuan Road, Shanghai, China 200032;

    Institutes of Biomedical Sciences, Fudan University, 138 Yi Xue Yuan Road, Shanghai, China 200032;

    Department of Hematology, Huashan Hospital, Fudan University, 12 Wulumuqi Road, Shanghai, China 200040;

    Department;

  • 会议组织
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    in vivo flow cytometry; in vivo fluorescence imaging; cancer metastasis; liver cancer; circulating cells; near-infrared; confocal imaging;

    机译:体内流式细胞仪体内荧光成像;癌症转移;肝癌;循环细胞近红外;共聚焦成像;
  • 入库时间 2022-08-26 14:30:56

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号